Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

On multiple phase 3 trials, treatment with STS101 resulted in numerical differences on primary outcome measures of pain freedom and freedom from the most bothersome symptoms.

FDA Accepts NDA for DHE Nasal Powder Product STS101 for Acute Migraine

Videos

The medical director of SleepMed in South Carolina discussed the need for more overall awareness of poor sleep and the risk factors associated with worsened heart health. [WATCH TIME: 3 minutes]

Improving Awareness of Sleep-Heart Associations and the Precursor Signs to Heart Issues: Richard Bogan, MD, FCCP, FAASM

Pitolisant, a therapy approved for patients with narcolepsy, is currently being assessed in 200 individuals with idiopathic hypersomnia, with change in excessive daytime sleepiness as the primary outcome.

Enrollment for Phase 3 INTUNE Study of Pitolisant in Idiopathic Hypersomnia Ahead of Schedule

Here's some of what is coming soon to NeurologyLive® this week.

This Week on NeurologyLive® — May 29, 2023

, has been with the team since September 2022. Follow her on Twitter 

As part of our monthly clinician spotlight, NeurologyLive® highlighted stroke expert Andrew Russman, DO, head of the Stroke Program and medical director of the Comprehensive Stroke Center at Cleveland Clinic.

NeurologyLive® Clinician of the Month Spotlight: Andrew Russman, DO

The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided perspective on the difficulties with testing agents for Parkinson disease psychosis, and the future outlook of treating the symptom. [WATCH TIME: 4 minutes]

Future of Treating Parkinson Disease Psychosis, Overcoming Challenges in Clinical Trials: Aaron Ritter, MD

Director of vascular neurology at NYU Langone.

The director of vascular neurology at NYU Langone Hospital in Brooklyn discussed the high prevalence of common risk factors for stroke, emphasizing the importance of early detection and management for prevention. [WATCH TIME: 4 minutes] 


Educating the Public on the Common Risk Factors for Stroke Awareness: Brandon Giglio, MD

, has been with the team since October 2019. Follow him on Twitter 

The senior associate consultant in the Department of Neurology at Mayo Clinic provided insight on an early feasibility study on the clinical impact of microburst vagus nerve stimulation in patients with drug-resistant epilepsy.

NeuroVoices: Cornelia Drees, MD, on The Advantages of Microburst Vagus Nerve Stimulation for Drug-Resistant Epilepsy

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

Authors